In the future, we will further validate the expression of TXN by expanding the sample size to include a more diverse patient population, encompassing patients with varying severity of sepsis, diverse demographic characteristics, and a broader range of underlying diseases, as well as by optimizing experimental conditions. This evidence concerns the gene TXN and Sepsis.